LUMIGAN® 0.03% (bimatoprost ophthalmic solution)
LUMIGAN®, approved by the U.S. Food and Drug Administration (FDA) in 2001, is indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Based on its efficacy and safety profile demonstrated over five years, LUMIGAN® received a first-line indication from the FDA in 2006 and is now used as an initial treatment in an increasing number of patients. LUMIGAN® offers a once-a-day dosing regimen. Maintaining once-daily dosing can help patients comply with therapy.
Glaucoma is the leading cause of preventable blindness in the United States1 and affects approximately 3 million people in the United States and 67 million people worldwide.2 Elevated IOP represents a major risk factor for vision loss associated with open-angle glaucoma; the higher the IOP, the greater the likelihood of optic nerve damage, which can lead to vision loss and potential blindness. LUMIGAN® delivers effective and sustained lowering of IOP,34 which is significant because elevated IOP is the only risk factor that can currently be treated. An estimated 3 to 6 million people in the United States have elevated IOP.5 Talk with your eye care professional about whether LUMIGAN® is right for you.
Important Safety Information
LUMIGAN® has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® is used. After stopping LUMIGAN®, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond five years are not known. The most common side effects are eye redness, growth of eyelashes, and itchy eyes.